Schjølseth S A, Hagen T, Ottestad L, Jakobsen E
Det Norske Radiumhospital, Oslo.
Tidsskr Nor Laegeforen. 1995 Nov 10;115(27):3371-3.
Mitomycin is a cytotoxic antibiotic that was first introduced into clinical use in 1958. Not until twenty years later was it recognised that haemolytic uremic syndrome could develop after treatment with mitomycin. It can be asked whether this condition was undiagnosed in previous years, since its frequency is now reported to be 4-15%. The disease appears to be dose-related, since it rarely occurs in patients who have received mitomycin < 30 mg/m2. No effective therapy has been established. We describe two patients with breast cancer in remission after treatment with mitomycin in combination with 5-fluorouracil. Both developed haemolytic uremic syndrome with fatal outcome.
丝裂霉素是一种细胞毒性抗生素，于1958年首次引入临床使用。直到二十年后，人们才认识到丝裂霉素治疗后可能会发生溶血性尿毒症综合征。有人会问，这种情况在过去几年是否未被诊断出来，因为现在报告的发生率为4% - 15%。该疾病似乎与剂量相关，因为在接受丝裂霉素< 30 mg/m²的患者中很少发生。尚未确立有效的治疗方法。我们描述了两名乳腺癌患者，她们在接受丝裂霉素与5-氟尿嘧啶联合治疗后病情缓解。两人均发生了溶血性尿毒症综合征并导致死亡。
